title: Successful Treatment of Conjunctival Lymphangiectasia With Subconjunctival Injection of Bevacizumab.
abstract: OBJECTIVE
  To report a novel intervention for the treatment of conjunctival lymphangiectasia-subconjunctival injection of bevacizumab.
  
  
  METHODS
  A 53-year-old white male presented with a 3-month history of right ocular discomfort and redness unresponsive to conventional topical treatment of lubricants and steroids. A clinical diagnosis of conjunctival lymphangiectasia was confirmed by biopsy. Bevacizumab (25 mg/mL) was injected subconjunctivally into the affected area.
  
  
  RESULTS
  An improvement in the degree of conjunctival chemosis was evident at 5 days postinjection. At 1-month follow-up, symptoms had fully resolved. No recurrence had been observed at 3 years' follow-up.
  
  
  CONCLUSIONS
  Subconjunctival bevacizumab injection may be an effective treatment for conjunctival lymphangiectasia.
authors.affiliation: *Department of Ophthalmology, Prince of Wales Hospital, Sydney, Australia; †Hispath, Specialist Pathologists, Sydney, Australia; and ‡Ophthalmic Surgeons, Sydney, Australia.
authors.forename: Jeremy C K
authors.initials: JC
authors.lastname: Tan
authors.forename: Stephen
authors.initials: S
authors.lastname: Mann
authors.forename: Minas T
authors.initials: MT
authors.lastname: Coroneo
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D003228:Conjunctiva / Q000187:drug effects; D003229:Conjunctival Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D056965:Injections, Intraocular; D008200:Lymphangiectasis / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D042601:Lymphatic Vessels / Q000378:metabolism; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism; D008875:Middle Aged; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D000098853:Podoplanin
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab; D008562:Membrane Glycoproteins; D042461:Vascular Endothelial Growth Factor A; C117468:PDPN protein, human; D000098853:Podoplanin; C467484:VEGFA protein, human